Suppr超能文献

病灶内注射胎盘组织液、透明质酸酶和地塞米松治疗口腔黏膜下纤维化疗效的比较评估:一项随机对照试验。

Comparative assessment of the efficacy of an intralesional injection of placentrex, hyaluronidase and dexamethasone in the management of oral submucous fibrosis: A randomized controlled trial.

作者信息

Goyal Jay, Iyer Shruthi, Palande Chinmayee, Brahmankar Ujwala, John Janice, Patil Kshitija

机构信息

Department of Oral Surgery, Jawahar Medical Foundation's ACPM Dental College, Dhule, Maharashtra 424001, India.

Department of Oral Medicine, Jawahar Medical Foundation's ACPM Dental College, Dhule, Maharashtra 424001, India.

出版信息

Med Int (Lond). 2024 Feb 26;4(2):19. doi: 10.3892/mi.2024.143. eCollection 2024 Mar-Apr.

Abstract

The prevalent symptoms of oral submucous fibrosis (OSMF) are a burning sensation and trismus. The aim of the present study was to compare the efficacy of placentrex, hyaluronidase and dexamethasone, and their combination in the treatment of OSMF. For this purpose, 160 patients with OSMF were divided into four groups (each with 40 patients at a 1:1:1:1 allocation ratio). The patients in group 1 (control) received only oral supplements, along with regular mouth-opening exercises; patients in group 2 received an injection of placental extract; patients in group 3 were injected with hyaluronidase and dexamethasone; and patients in group 4 received a combination of injections from groups 2 and 3. The injections were administered once weekly for 12 weeks and patients were followed-up for 12 months. The data of the patients (mouth opening ability and a burning sensation) were analyzed using ANOVA and the Kruskal-Wallis test. The maximum increase in mouth opening (7.30±0.80 mm) was noted in group 4, and the lease increase was observed in the control group (0.37±0.16 mm), from baseline levels to the end of the 12th week. The maximum relapse in mouth opening of 1.62±0.45 mm was noted in group 2, and a minimum relapse of 0.20±0.08 mm was noted in group 4. On the whole, the present study demonstrates that the intralesional injection of a combination of the three drugs (placentrex, hyaluronidase and dexamethasone) in addition to the use of oral supplements and mouth opening exercises has a high level of efficacy in improving trismus and burning sensation in patients with OSMF.

摘要

口腔黏膜下纤维化(OSMF)的常见症状是烧灼感和张口受限。本研究的目的是比较胎盘组织液、透明质酸酶和地塞米松及其联合用药治疗OSMF的疗效。为此,将160例OSMF患者分为四组(每组40例,分配比例为1:1:1:1)。第1组(对照组)患者仅接受口服补充剂,并进行常规张口训练;第2组患者注射胎盘提取物;第3组患者注射透明质酸酶和地塞米松;第4组患者接受第2组和第3组注射药物的联合治疗。每周注射一次,共12周,并对患者进行12个月的随访。使用方差分析和Kruskal-Wallis检验分析患者的数据(张口能力和烧灼感)。从基线水平到第12周结束时,第4组的张口最大增加量为(7.30±0.80 mm),对照组的增加量最小(0.37±0.16 mm)。第2组的张口最大复发量为1.62±0.45 mm,第4组的最小复发量为0.20±0.08 mm。总体而言,本研究表明,除了使用口服补充剂和张口训练外,病灶内注射三种药物(胎盘组织液、透明质酸酶和地塞米松)的组合对改善OSMF患者的张口受限和烧灼感具有很高的疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d9d/10928652/f58050101fd1/mi-04-02-00143-g00.jpg

相似文献

7
Comparison of Efficacy of Lycopene and Lycopene-Hyaluronidase Combination in the Treatment of Oral Submucous Fibrosis.
J Pharm Bioallied Sci. 2019 May;11(Suppl 2):S260-S264. doi: 10.4103/JPBS.JPBS_6_19.
8
The study of placentrex and hydrocortisone as an adjunct treatment in oral submucous fibrosis.
J Family Med Prim Care. 2020 May 31;9(5):2469-2474. doi: 10.4103/jfmpc.jfmpc_268_20. eCollection 2020 May.
9
Evaluation of Clinical Profile and Various Treatment Modalities in Oral Sub Mucous Fibrosis in North India: Our Experience.
Indian J Otolaryngol Head Neck Surg. 2022 Dec;74(Suppl 3):6313-6320. doi: 10.1007/s12070-021-03049-y. Epub 2022 Jan 8.

引用本文的文献

1
Physiotherapy in improving the interincisal mouth opening in oral submucous fibrosis: Meta-analysis.
J Oral Biol Craniofac Res. 2025 Jul-Aug;15(4):677-683. doi: 10.1016/j.jobcr.2025.04.007. Epub 2025 Apr 18.

本文引用的文献

1
Exosomes Derived from Human Adipose Mesenchymal Stem Cells Inhibits Fibrosis and Treats Oral Submucous Fibrosis via the miR-181a-5p/Smad2 Axis.
Tissue Eng Regen Med. 2024 Jan;21(1):123-135. doi: 10.1007/s13770-023-00579-0. Epub 2023 Sep 27.
2
The Immunolocalization of Mast Cells in the Pathology of Oral Submucous Fibrosis.
Cureus. 2023 Jun 6;15(6):e40069. doi: 10.7759/cureus.40069. eCollection 2023 Jun.
4
Comparative effectiveness of medicinal interventions for oral submucous fibrosis: A network meta-analysis.
J Stomatol Oral Maxillofac Surg. 2023 Jun;124(3):101423. doi: 10.1016/j.jormas.2023.101423. Epub 2023 Feb 11.
5
Study of Efficacy of Intraoral Submucosal Injections of Corticosteroids and Placentrex in the Management of Oral Submucous Fibrosis.
Indian J Otolaryngol Head Neck Surg. 2022 Oct;74(Suppl 2):1996-2001. doi: 10.1007/s12070-020-01965-z. Epub 2020 Jul 14.
6
Evaluation of Hematological Profile in Oral Submucous Fibrosis.
Cureus. 2022 Feb 5;14(2):e21926. doi: 10.7759/cureus.21926. eCollection 2022 Feb.
7
Correlation of Clinical Features in Oral Submucous Fibrosis: A 9-Year Retrospective Study.
Ethiop J Health Sci. 2022 Jan;32(1):137-144. doi: 10.4314/ejhs.v32i1.15.
8
Research Achievements of Oral Submucous Fibrosis: Progress and Prospect.
Biomed Res Int. 2021 Mar 18;2021:6631856. doi: 10.1155/2021/6631856. eCollection 2021.
9
Oral Submucous Fibrosis: A Review on Biomarkers, Pathogenic Mechanisms, and Treatments.
Int J Mol Sci. 2020 Sep 30;21(19):7231. doi: 10.3390/ijms21197231.
10
Medicinal management of oral submucous fibrosis in the past decade- A systematic review.
J Oral Biol Craniofac Res. 2020 Oct-Dec;10(4):552-568. doi: 10.1016/j.jobcr.2020.08.004. Epub 2020 Aug 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验